These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 34330017)

  • 1. COVID-19 vaccines.
    Ndwandwe D; Wiysonge CS
    Curr Opin Immunol; 2021 Aug; 71():111-116. PubMed ID: 34330017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
    Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
    Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):161-162. PubMed ID: 34089030
    [No Abstract]   [Full Text] [Related]  

  • 6. Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.
    Zhu C; Pang S; Liu J; Duan Q
    Drugs; 2024 Apr; 84(4):403-423. PubMed ID: 38652356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efforts towards a COVID-19 vaccine.
    Brüssow H
    Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of COVID-19 (Pre)Clinical Vaccine Development.
    Ye T; Zhong Z; García-Sastre A; Schotsaert M; De Geest BG
    Angew Chem Int Ed Engl; 2020 Oct; 59(43):18885-18897. PubMed ID: 32663348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Key Role of Nucleic Acid Vaccines for One Health.
    Fomsgaard A; Liu MA
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33567520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
    Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief review of the mRNA vaccines COVID-19.
    Vitiello A; Ferrara F
    Inflammopharmacology; 2021 Jun; 29(3):645-649. PubMed ID: 33932192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies.
    Rele S
    Hum Vaccin Immunother; 2021 Apr; 17(4):1122-1127. PubMed ID: 32993453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.
    Funk CD; Laferrière C; Ardakani A
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development.
    Singh R; Kang A; Luo X; Jeyanathan M; Gillgrass A; Afkhami S; Xing Z
    FASEB J; 2021 Mar; 35(3):e21409. PubMed ID: 33577115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.